IP Library Patent Application 16486211
Patent Application
App. No. 16/486,211

Small Molecule Inhibition of Micro-RNA-210 Reprograms an Oncogenic Hypoxic Circuit

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/486,211
Abstract

Herein, we describe the identification of a small molecule named Targapremir-210 that binds to the Dicer site of the miR-210 hairpin precursor. This interaction inhibits production of the mature miRNA, de-represses glycerol-3-phosphate dehydrogenase 1-like enzyme (GPD1 L), a hypoxia-associated protein negatively regulated by miR-210, decreases HIF-1 a, and triggers apoptosis of triple negative breast cancer cells only under hypoxic conditions. Further, Targapremir-210 inhibits tumorigenesis in a mouse xenograft model of hypoxic triple negative breast cancer. We applied Chemical Cross-Linking and Isolation by Pull Down (Chem-CLIP) to study the cellular selectivity and the on- and off-targets of Targapremir-210. Targapremir-210 selectively recognizes the miR-210 precursor and can differentially recognize RNAs in cells that have the same target motif but have different expression levels, revealing this important feature for selectively drugging RNAs for the first time.

Claims (5)

1 . A method of inhibiting biogenesis of microRNA miR-210 in a cell under hypoxic conditions, comprising contacting the cell with an effective amount or concentration of a compound of formula

2 . The method of claim 1 , wherein the Targapremir-210 selectively recognizes the miR-210 precursor and can differentially recognize RNAs in cells that have the same target motif but have different expression levels.

3 . A method of target profiling a set of cells for expression of a miR-210 microRNA precursor, comprising administering an effective amount or concentration of Targapermir-210 to the set of cells, then screening the set of cells for expression or suppression of a phenotype associated with miR-210.

4 . A method of impeding tumor proliferation in a mammal in vivo, comprising administering to the animal an effective dose of a compound of of formula

5 . The method of claim 4 , wherein the tumor is breast cancer.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2022
From: THE SCRIPPS RESEARCH INSTITUTE
To: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
Reel/Frame 061177/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2022
From: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 061177/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2022
From: DISNEY, MATTHEW D.
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 059321/0341 →